Skip to content
10-Q

Quarterly Report

ACCUSTEM SCIENCES, INC. ACUT

0001493152-24-046438

← back to feed
Filed
Nov 18, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 18, 2024 11.35M sh
Current Liabilities Q3 2024 · Sep 30, 2024 $3.3M
Current Liabilities Q3 2024 · Dec 31, 2023 $2.25M
Total Liabilities Q3 2024 · Sep 30, 2024 $3.3M
Total Liabilities Q3 2024 · Dec 31, 2023 $2.25M
Current Assets Q3 2024 · Sep 30, 2024 $102.49K
Current Assets Q3 2024 · Dec 31, 2023 $129.85K
Total Assets Q3 2024 · Sep 30, 2024 $103.82K
Total Assets Q3 2024 · Dec 31, 2023 $133.9K
Shares Diluted Q3 2024 · Sep 30, 2023 11.35M sh
Shares Diluted Q3 2024 · Sep 30, 2023 11.35M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$1.32M
Stockholders Equity Q3 2024 · Sep 30, 2023 −$1.89M
Stockholders Equity Q3 2024 · Jun 30, 2023 −$1.31M
Stockholders Equity Q3 2024 · Dec 31, 2022 −$139.55K
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.05
Eps Diluted Q3 2024 · Sep 30, 2023 −$0.16
Eps Basic Q3 2024 · Sep 30, 2023 −$0.05
Eps Basic Q3 2024 · Sep 30, 2023 −$0.16
Sga Expense Q3 2024 · Sep 30, 2023 $578.57K
Sga Expense Q3 2024 · Sep 30, 2023 $1.75M
Rd Expense Q3 2024 · Sep 30, 2023 $19.95K
Rd Expense Q3 2024 · Sep 30, 2023 $50.13K
Net Income Q3 2024 · Sep 30, 2023 −$598.53K
Net Income Q3 2024 · Sep 30, 2023 −$1.8M
Operating Income Q3 2024 · Sep 30, 2023 −$598.53K
Operating Income Q3 2024 · Sep 30, 2023 −$1.8M